Literature DB >> 11567805

An implementation strategy for IMRT of ethmoid sinus cancer with bilateral sparing of the optic pathways.

F Claus1, W De Gersem, C De Wagter, R Van Severen, I Vanhoutte, W Duthoy, V Remouchamps, B Van Duyse, L Vakaet, M Lemmerling, H Vermeersch, W De Neve.   

Abstract

PURPOSE: To develop a protocol for the irradiation of ethmoid sinus cancer, with the aim of sparing binocular vision; of developing a strategy of intensity-modulated radiation therapy (IMRT) planning that produces dose distributions that (1) are consistent with the protocol prescriptions and (2) are deliverable by static segmental IMRT techniques within a 15-minute time slot; of fine tuning the implementation strategy to a class solution approach that is sufficiently automated and efficient, allowing routine clinical application; of reporting on the early clinical implementation involving 11 patients between February 1999 and July 2000. patients and methods: Eleven consecutive T1-4N0M0 ethmoid sinus cancer patients were enrolled in the study. For Patients 1-8, a first protocol was implemented, defining a planning target volume prescription dose of 60 to 66 Gy in 30-33 fractions and a maximum dose (Dmax) of 50 Gy to optic pathway structures and spinal cord and limit of 60 Gy to brainstem. For Patients 9-11, an adapted (now considered mature) protocol was implemented, defining a (planning target volume) prescription dose of 70 Gy in 35 fractions and a Dmax to optic pathway structures and brainstem of 60 Gy and to spinal cord of 50 Gy.
RESULTS: The class solution-directed strategy developed during this study reduced the protocol translation process from a few days to about 2 hours of planner time. The mature class solution involved the use of 7 beam incidences (20-37 segments), which could be delivered within a 15-minute time slot. Acute side effects were limited and mild. None of the patients developed dry eye syndrome or other visual disturbances. The follow-up period is too short for detection of retinopathy or optic nerve and chiasm toxicity.
CONCLUSION: Conventional radiotherapy of ethmoid sinus tumors is associated with serious morbidity, including blindness. We hypothesize that IMRT has the potential to save binocular vision. The dose to the optic pathway structures can be reduced selectively by IMRT. Further enrollment of patients and longer follow-up will show whether the level of reduction tested by the clinical protocol is sufficient to save binocular vision. An adaptive strategy of IMRT planning was too inefficient for routine clinical practice. A class solution-directed strategy improved efficiency by eliminating human trial and error during the IMRT planning process.

Entities:  

Mesh:

Year:  2001        PMID: 11567805     DOI: 10.1016/s0360-3016(01)01627-3

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  12 in total

1.  [Intensity modulated radiotherapy (IMRT) of head and neck tumors. Increased biological effectiveness in high-risk situations by "integrated boost" therapy].

Authors:  D Milanovic; F Lohr; K Götte; B Dobler; B Hermann; K Hörmann; F Wenz
Journal:  HNO       Date:  2004-08       Impact factor: 1.284

2.  A comprehensive comparative analysis of treatment modalities for sinonasal malignancies.

Authors:  Tyler P Robin; Bernard L Jones; Oren M Gordon; Andy Phan; Diana Abbott; Jessica D McDermott; Julie A Goddard; David Raben; Ryan M Lanning; Sana D Karam
Journal:  Cancer       Date:  2017-04-03       Impact factor: 6.860

3.  Coplanar VMAT vs. noncoplanar VMAT in the treatment of sinonasal cancer.

Authors:  Ning Zhong-Hua; Jiang Jing-Ting; Li Xiao-Dong; Mu Jin-Ming; Mo Jun-Chong; Jin Jian-Xue; Gao Ming; Li Qi-Lin; Gu Wen-Dong; Chen Lu-Jun; Pei Hong-Lei
Journal:  Strahlenther Onkol       Date:  2014-10-08       Impact factor: 3.621

Review 4.  Intensity-modulated radiotherapy for carcinoma of the head and neck.

Authors:  José A Peñagarícano; Niko Papanikolaou
Journal:  Curr Oncol Rep       Date:  2003-03       Impact factor: 5.075

5.  Comparison of a Hybrid IMRT/VMAT technique with non-coplanar VMAT and non-coplanar IMRT for unresectable olfactory neuroblastoma using the RayStation treatment planning system-EUD, NTCP and planning study.

Authors:  Vijay P Raturi; Atsushi Motegi; Sadamoto Zenda; Naoki Nakamura; Hidehiro Hojo; Shin-Ichiro Kageyama; Masayuki Okumura; Toshiya Rachi; Hajime Ohyoshi; Hidenobu Tachibana; Kana Motegi; Takaki Ariji; Masaki Nakamura; Yasuhiro Hirano; Hidenari Hirata; Tetsuo Akimoto
Journal:  J Radiat Res       Date:  2021-05-12       Impact factor: 2.724

6.  A Patient Selection Approach Based on NTCP Models and DVH Parameters for Definitive Proton Therapy in Locally Advanced Sinonasal Cancer Patients.

Authors:  Alfredo Mirandola; Stefania Russo; Maria Bonora; Barbara Vischioni; Anna Maria Camarda; Rossana Ingargiola; Silvia Molinelli; Sara Ronchi; Eleonora Rossi; Alessandro Vai; Nicola Alessandro Iacovelli; Juliette Thariat; Mario Ciocca; Ester Orlandi
Journal:  Cancers (Basel)       Date:  2022-05-28       Impact factor: 6.575

Review 7.  Intensity modulated radiotherapy for sinonasal malignancies with a focus on optic pathway preservation.

Authors:  Alexander Chi; Nam P Nguyen; William Tse; Gill Sobremonte; Patrick Concannon; Angela Zhu
Journal:  J Hematol Oncol       Date:  2013-01-07       Impact factor: 17.388

Review 8.  Management of paranasal sinus malignancy.

Authors:  Terry A Day; Ricardo A Beas; Rodney J Schlosser; Bradford A Woodworth; Julio Barredo; Anand K Sharma; M Boyd Gillespie
Journal:  Curr Treat Options Oncol       Date:  2005-01

9.  Quantitative comparison of volumetric modulated arc therapy and intensity modulated radiotherapy plan quality in sino-nasal cancer.

Authors:  Marimuthu Sankaralingam; Martin Glegg; Suzanne Smith; Allan James; Mohammed Rizwanullah
Journal:  J Med Phys       Date:  2012-01

10.  Dosimetric comparison between coplanar and non coplanar field radiotherapy for ethmoid sinus cancer.

Authors:  Antoine Serre; Katia Idri; Pascal Fenoglietto; Norbert Ailleres; Lore Santoro; Claire Lemanski; Renaud Garrel; Marc Makeieff; Ali Allaw; Jean-Bernard Dubois; David Azria
Journal:  Radiat Oncol       Date:  2007-09-18       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.